Provider Resource Center

The VDP is our ever-expanding platform for cancer test development, validation and continued innovation. It uniquely integrates whole-ome data from every test we perform, real-world and other clinical data, along with our world-class AI capabilities to help advance scientific understanding of cancer and advance new opportunities to improve patient care.

Veracyte offers laboratory developed tests (LDTs) performed in our CLIA-certified, high-complexity labs for four cancer types: thyroid, prostate, bladder, and breast.

The Prosigna Breast Cancer Prognostic Gene Signature Assay is available as a CE-IVD test outside the US — to find out if it is available in your country, or for information about reimbursement and insurance coverage, contact us at [email protected].

Our tests provide clinicians with insights based on each patient’s unique tumor biology to help guide personalized treatment decisions. To learn more, visit Technology and Pipeline.

Our MRD approach is unique because we perform whole-genome testing at every step—from the initial test to determine a tumor’s unique molecular fingerprint to then looking for that same molecular fingerprint in the patient’s blood samples over time to indicate whether or not the cancer has returned. We believe this approach enables us to provide a more efficient and effective test in the near term and also generates robust data that will allow us to partner with the research community to unlock new cancer insights that can further advance patient care.

We are continuing to advance our digital pathology capabilities and research to assess how this technology can complement and potentially enhance our molecular testing capabilities. In addition, we are sharing our digital pathology services and associated AI models with research collaborators to further the science in the field of combined AI-based imaging and molecular analysis.

We work to make our laboratory developed tests (LDTs) accessible to patients. Medicare and many commercial insurance plans cover our molecular tests in the United States. We also offer billing support, financial assistance, and flexible payment options. Some restrictions apply.

Veracyte is headquartered in South San Francisco, California, with offices in San Diego as well as Austin, Texas, and Haifa, Israel.